論文

国際誌
2022年2月

Treatment Efficacy of PD-1 Inhibitor Therapy in Patients With Recurrent and/or Metastatic Salivary Gland Carcinoma.

Anticancer research
  • Kazuki Hashimoto
  • Ryuji Yasumatsu
  • Ryosuke Kuga
  • Takahiro Hongo
  • Hidetaka Yamamoto
  • Mioko Matsuo
  • Takahiro Wakasaki
  • Rina Jiromaru
  • Tomomi Manako
  • Satoshi Toh
  • Muneyuki Masuda
  • Moriyasu Yamauchi
  • Yuichiro Kuratomi
  • Hideoki Uryu
  • Torahiko Nakashima
  • Akihiro Tamae
  • Risa Tanaka
  • Masahiko Taura
  • Toranoshin Takeuchi
  • Takamasa Yoshida
  • Takashi Nakagawa
  • 全て表示

42
2
開始ページ
981
終了ページ
989
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.21873/anticanres.15558

BACKGROUND/AIM: The efficacy of programmed cell death 1 (PD-1) inhibitor therapy for patients with recurrent and/or metastatic salivary gland carcinoma (R/M SGC) remains unclear. PATIENTS AND METHODS: We retrospectively analyzed 36 patients with R/M SGC treated with PD-1 inhibitor. The expression of programmed cell death ligand 1 (PD-L1) and mismatch repair (MMR) proteins was also analyzed. RESULTS: The objective response rate (ORR) was 11.1%. The histopathological subtypes of patients who achieved complete response or partial response were salivary duct carcinoma (SDC) in three patients and poorly differentiated carcinoma in one patient, all of whom showed a positive PD-L1 expression. The expression of MMR proteins was not associated with the efficacy of PD-1 inhibitors. CONCLUSION: Although the efficacy of PD-1 inhibitor therapy in R/M SGC is limited, certain patients may respond and achieve long-term disease control. There is a potential therapeutic effect in SDC patients with positive PD-L1 expression.

リンク情報
DOI
https://doi.org/10.21873/anticanres.15558
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/35093898
ID情報
  • DOI : 10.21873/anticanres.15558
  • PubMed ID : 35093898

エクスポート
BibTeX RIS